Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of	entit	y

Slater & Gordon Limited

ABN

93 097 297 400

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

⁺Class of ⁺securities issued or to be issued

Securities issued to certain lenders of the Company under the Company's Syndicated Facility Agreement ("Facility") which may entitle those lenders to ordinary shares in the Company on the terms described in item 3 ("Warrants")

Number of *securities issued or to be issued (if known) or maximum number which may be issued Warrants for the issuance of up to an expected maximum of 21,987,678 ordinary shares which reflect the terms described in item 3. The maximum number of ordinary shares that may be issued under the Warrants has been calculated based on a notional maximum theoretical uplift in share price, and (A) the Company's current number of ordinary shares on issue; and (B) the spot AUD/GBP exchange rate of 0.523 AUD/GBP as at 29 April 2016. The expected maximum number of ordinary shares that may be issued under the Warrants represents approximately 6.24% of the Company's current ordinary shares on issue.

⁺ See chapter 19 for defined terms.

Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)

The Warrants provide for a placement of ordinary shares on the refinancing or maturity of the Facility by reference to any uplift in the market capitalisation of the Company from 29 April 2016 to the date of such refinancing or maturity. Accordingly, based on the lenders' current level of commitments, the maximum expected dilutive impact of ordinary shares issued to warrant holders is approximately 6.24% of the current issued ordinary shares in the Company.

The actual number of ordinary shares issued under the Warrants will, in respect of those lenders who hold Warrants, depend on each lender's share of the total commitments provided to the Company at the date of issuance of the ordinary shares. (Commitments are denominated in either GBP and AUD, and uplift in market capitalisation will be calculated and denominated in AUD).

Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Issuance of ordinary shares the subject of the Warrants will rank equally with existing fully paid ordinary shares on issue.

5 Issue price or consideration

Warrants issued in lieu of amendment fees under the Facility

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Warrants issued in lieu of amendment fees under the Facility
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No.
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	Refer to item 1
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued	N/A
	under an exception in rule 7.2	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A

⁺ See chapter 19 for defined terms.

6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1	
7	⁺ Issue dates	4 Juno 2016	
7	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.	4 June 2016	
	Cross reference: item 33 of Appendix 3B.		
		Г	T. at
_		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	352,377,933	Fully paid ordinary shares
		Number	+Class
9	Number and +class of all +securities not quoted on ASX	496,000	Performance Rights
	(including the +securities in section 2 if applicable)	105,000	VCR Shares
		Up to 21,987,678	Warrants
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the	N/A

⁺ See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	N/A
	3 - Quotation of securitie	
34	Type of *securities (tick one)	
(a)	*Securities described in Part	1
(b)	All other *securities	
	•	nd of the escrowed period, partly paid securities that become fully paid en restriction ends, securities issued on expiry or conversion of convertible

+ See chapter 19 for defined terms.

Appendix 3B Page 6 04/03/2013

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to docume	e you are providing the information or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional *securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	⁺ Class of ⁺ securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number N/A	⁺ Class

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 +securities to be quoted under section 1019B of the Corporations Act at
 the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	(Company secretary)	Date: 6 June 2016
Print name:	Bryce Houghton	

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate "A", the base figures capacity is calculated	ure from which the placement
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	350,719,894
Add the following:	
Number of fully paid ⁺ ordinary securities issued in that 12 month period under an exception in rule 7.2	1,658,039
Number of fully paid ⁺ ordinary securities issued in that 12 month period with shareholder approval	NIL
Number of partly paid ⁺ ordinary securities that became fully paid in that 12 month period	NIL
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	NIL.
"A"	352,377,933

Appendix 3B Page 10 04/03/2013

⁺ See chapter 19 for defined terms.

Stop 2: Coloulate 45% of "A"		
Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
Multiply "A" by 0.15	52,856,690	
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule	
Insert number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	21,987,678	
Under an exception in rule 7.2		
Under rule 7.1A		
 With security holder approval under rule 7.1 or rule 7.4 		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	21,987,678	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	52,856,690	
Note: number must be same as shown in Step 2		
Subtract "C"	21,987,678	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	30,869,012	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

nent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
N/A	
0.10	
Note: this value cannot be changed	
of placement capacity under rule	

Appendix 3B Page 12 04/03/2013

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"		
Note: number must be same as shown in Step 3		
Total ["A" x 0.10] – "E"		
	Note: this is the remaining placement capacity under rule 7.1A	

⁺ See chapter 19 for defined terms.